pharma · Congenital Adrenal Hyperplasia · Polycystic Ovary Syndrome · SPRB
SPRUCE BIOSCIENCES
SPRUCE BIOSCIENCES, INC.
SPRUCE BIOSCIENCES clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2016
- Employees
- 27
- Programs
- 5
- Drugs
- 3
- Patents
- 9
SPRUCE BIOSCIENCES projects
5 ClinicalTrials.gov programs sponsored by SPRUCE BIOSCIENCES.
SPRUCE BIOSCIENCES has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Tralesinidase alfa (TA)
SPRUCE BIOSCIENCES, INC.
MPS IIIB
1 trial -
SPR001
SPRUCE BIOSCIENCES, INC.
Congenital Adrenal Hyperplasia
2 trials -
Tildacerfont
SPRUCE BIOSCIENCES, INC.
Congenital Adrenal Hyperplasia
1 trial -
Tildacerfont
SPRUCE BIOSCIENCES, INC.
Polycystic Ovary Syndrome
1 trial -
Tildacerfont/Placebo
SPRUCE BIOSCIENCES, INC.
Congenital Adrenal Hyperplasia
2 trials
Frequently asked questions
How many clinical projects does SPRUCE BIOSCIENCES have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.